IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, September 2026
Impact Factor: 8.2

Pharmacogenomics-Guided Personalized Pharmacotherapy: Optimizing Drug Selection, Dosing, and Clinical Outcomes

Dr. Kolli Narendra Kumar Reddy[1], Dr. Ch. Veera Babu[2], Y. Jhansi[3], S. Madhavi[4], Ch. Maheswari[5], N. Raga Sruthi[6],
[1]Professor, [2]Associate Professor,
Vikas Group of Institutions, Vijayawada

Abstract: *Pharmacogenomics (PGx) is an important aspect of precision medicine that looks at differences in response to medications on a genetic level. Standard pharmacotherapy does not fully consider the potential for genetic differences in drug metabolism, transport, effectiveness and side effects. Personalized pharmacotherapy with PGx provides integration of genetic and clinical data for optimum drugs and dosages. Clinically relevant gene–drug associations such as CYP2C19 and clopidogrel, CYP2C9/VKORC1 and warfarin, TPMT and thiopurines, DPYD and fluoropyrimidines, and HLA variants and drug hypersensitivity suggest that it can be used to facilitate the safety and efficacy of drug treatment. But there are problems with the cost of testing, availability, interpretation, evidence gaps, diversity of populations, privacy, remuneration, and integration into healthcare systems. This paper explores how PGx can be used to optimize drug selection, dose, and clinical outcomes, the need for evidence-based guidelines, clinical decision support, multi-disciplinary teamwork, and equitable access to pharmacogenomic testing.*

Keywords: Pharmacogenomics, Personalized Medicine, Precision Medicine, Pharmacotherapy, Drug Selection, Dose Optimization, Adverse Drug Reactions, Genetic Testing, Clinical Outcomes, Pharmacogenetic-Guided Therapy

I. INTRODUCTION

Not everybody reacts in the same way to medicine. A medication that works well for one person may not work for another, even if the doses are the same. This variation can be due to age, sex, organ function, disease characteristics, concurrent medications, adherence, environment and genetics. Genetic variation may have a profound effect on pharmacokinetics and pharmacodynamics of drug metabolism, transport, efficacy and toxicity.

Pharmacogenomics (PGx): The study of the effects of genetic differences on the way people respond to specific drugs. It will be a vital bridge connecting the science of the genome to therapeutic use in the clinic and will be useful in determining which patients would be more likely to respond to specific drugs or have a failure of response, as well as identifying those who are likely to have side reactions. The U.S. Food and Drug Administration (FDA) has identified several pharmacogenomic biomarkers for drug labelling, some of which could be associated with altered response to a drug, drug safety, altered drug exposure, or genotype-specific dosing.

Traditional pharmacotherapy is mostly population based and may not fully consider inter-individual variance in genetic makeup. PGx-guided therapy is more personalized, as it combines genetic data with traditional clinical data to assist in selecting drugs and optimizing their doses.

However, evidence-based resources like the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG), That convert genetic information into clinically relevant prescribing recommendations, have supported clinical implementation. However, there are some challenges, such as the cost of the test, availability, interpretation, gaps in evidence, and integrating the test into the healthcare system.

This paper reviews the application of personalized pharmacotherapy based on pharmacogenomics to select the right drugs, doses, ensure treatment safety, and maximize clinical benefits.

DOI: 10.48175/568

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, September 2026
Impact Factor: 8.2

II. LITERATURE REVIEW

Mosch et al. (2025)[1] have reviewed the current practice and future potential of pharmacogenetic panel testing. A significant percentage of people have at least one potentially actionable pharmacogenetic variant, the authors wrote, suggesting that pre-therapeutic panel testing could aid in informed prescribing decisions for many different drugs. Based on the current evidence, the review recommended implementation of pre-therapeutic PGx panel testing of drugs with established PGx guidelines. The authors did, however, highlight the need for additional studies to determine which patient populations might best benefit from these and what the cost-effectiveness of widespread implementation might be.

In the PREPARE multicentre, controlled, cluster-randomised implementation study of European health care settings, **Swen et al. (2023)**[2] examined the clinical value of a 12-gene pharmacogenetic panel. The study showed that prescribing based on genotype led to a significant decrease in adverse drug reactions with clinical relevance as compared with conventional treatment. Results are important to note as evidence that pre-emptive multi-gene testing may be useful in addition to single-gene testing, after treatment has been chosen. The study has been able to prove the feasibility of pharmacogenomic integration in hospitals, CHCs and community pharmacies.

Kabbani et al. (2023)[3] discussed the implementation of pharmacogenomics in actual clinical scenarios and suggested an implementation strategy that relies on the identification of actionable gene-drug pairs, the selection of a suitable test, the interpretation of the genetic result, and integrating the genetic information with the electronic health record and clinical decision-support systems. The authors stressed that cooperation of health care providers, pharmacists, laboratories, information-Technology professionals, institutional leaders, and other stakeholders is essential for successful implementation. The review also separated out reactive testing at the point of care and pre-emptive testing and emphasized the pros and cons of candidate-gene versus panel-based testing.

Medwid and Kim (2022)[4] provided an overview of how pharmacogenomics is currently being used and highlighted how the availability of testing and turnaround times have been enhanced making clinical pharmacogenomics testing more possible. The authors mentioned clinically relevant practices, such as the use of DPYD genotyping in the treatment of fluoropyrimidines, and the possibility that pre-emptive testing could become a crucial part of personalized medicine. The review also noted some weaknesses in the presentations of diverse populations, the inappropriateness of some evidence, and challenges to implementing widely. The study provides further evidence that a proper clinical workflow and clinical information should be integrated with the pharmacogenomic evidence to make best use of the information.

In the TAILOR-PCI randomized clinical trial of patients undergoing PCI, the researchers compared genotype-guided selection of oral P2Y12 inhibitors to conventional clopidogrel therapy **Pereira et al.(2020)**[5]**.** The study compared the

---

[1]Mosch, R., van der Lee, M., Guchelaar, H. J., & Swen, J. J. (2025). Pharmacogenetic panel testing: A review of current practice and potential for clinical implementation. *Annual Review of Pharmacology and Toxicology, 65*(1), 91–109.

[2]Swen, J. J., van der Wouden, C. H., Manson, L. E. N., Abdullah-Koolmees, H., Blagec, K., Blagus, T., Böhringer, S., Cambon-Thomsen, A., Cecchin, E., Cheung, K. C., Deneer, V. H., Dupui, M., Ingelman-Sundberg, M., Jonsson, S., Joefield-Roka, C., Just, K. S., Karlsson, M. O., Konta, L., Koopmann, R., ... Guchelaar, H. J. (2023). A 12-gene pharmacogenetic panel to prevent adverse drug reactions: An open-label, multicentre, controlled, cluster-randomised crossover implementation study. *The Lancet, 401*(10374), 347–356.

[3]Kabbani, D., Akika, R., Wahid, A., Daly, A. K., Cascorbi, I., & Zgheib, N. K. (2023). Pharmacogenomics in practice: A review and implementation guide. *Frontiers in Pharmacology, 14*, 1189976.

[4]Medwid, S., & Kim, R. B. (2024). Implementation of pharmacogenomics: Where are we now? *British Journal of Clinical Pharmacology, 90*(8), 1763–1781.

[5]Pereira, N. L., Farkouh, M. E., So, D., Lennon, R., Geller, N., Mathew, V., Bell, M., Bae, J.-H., Jeong, M. H., Chavez, I., Gordon, P., Abbott, J. D., Cagin, C., Baudhuin, L., Fu, Y.-P., Goodman, S. G., Hasan, A., Iturriaga, E., Lerman, A.,

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 1, September 2026 Impact Factor: 8.2

ischemic cardiovascular outcomes of patients with loss-of-function genotype with the outcomes of those who did not. The prespecified analysis was not statistically significant, but the genotype-guided strategy did yield a lower rate of the primary endpoint, numerically. The study results show that a specific gene–drug interaction that is identified in a clinical context does not automatically lead to better clinical outcomes in all cases. The study thus underscores the need to assess pharmacogenomic interventions using a rigorous clinical trial approach, not just on the basis of biological plausibility.

III. METHODOLOGY

3.1 Research Design

The study used a narrative literature review and conceptual research design approaches to analyze the role of pharmacogenomics informed personalized pharmacotherapy in improving drug selection and dosage optimization, treatment safety, and clinical treatment outcomes. The study does not include primary patient information, laboratory testing, or primary clinical intervention. Rather, it combines published scientific evidence, clinical guidelines, regulatory information and implementation research.

3.2 Literature Search Strategy

Major biomedical and multidisciplinary databases, e.g., PubMed, Scopus, and Web of Science, were searched for relevant literature, as well as authoritative sources like the U.S. Food and Drug Administration (FDA), Clinical Pharmacogenetics Implementation Consortium (CPIC), and Dutch Pharmacogenetics Working Group (DPWG).

The combinations of these keywords were used as search terms, including: pharmacogenomics, pharmacogenetics, personalized pharmacotherapy, precision medicine, drug selection, dose optimization, adverse drug reactions, gene–drug interactions, clinical outcomes, CYP2C19, CYP2C9, VKORC1, TPMT, NUDT15, DPYD, and HLA.

3.3 Inclusion and Exclusion Approach

Peer-reviewed research articles, clinical trials, system and narrative reviews, clinical practice guidelines, implementation studies and regulatory documents of relevance to pharmacogenomics and medication therapy received priority. Special emphasis was placed on clinically relevant interaction between genes and drugs and data pertaining to patient safety, therapeutic efficacy and dosage and implementation.

Articles were given a lower priority if they were not clinical pharmacotherapy related, were not relevant to the research aims, or were only concerned with basic genomic mechanisms and not how this would relate to treatment with medication.[6]

3.4 Data Synthesis

The literature identified was grouped in 4 major themes: (1) pharmacogenomics and drug response, (2) drug selection and dosage optimization, (3) prevention of adverse drug reactions, and (4) clinical implementation and outcomes. Evidence from individual studies was compared based on the strength of the gene–drug association, therapeutic indication, clinical outcomes and implementation needs.

The method thus offers a conceptual synthesis of the existing evidence in a structured way and takes into account the variability of pharmacogenomic recommendations between drugs, populations, and clinical settings.[7]

... Rihal, C. (2020). Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: The TAILOR-PCI randomized clinical trial. *JAMA, 324*(8), 761–771.

[6]Caudle, K. E., Whirl-Carrillo, M., Relling, M. V., Hoffman, J. M., Donnelly, R. S., Haidar, C. E., Bourque, M. S., Frear, S., Gong, L., Sangkuhl, K., Whaley, R., & Klein, T. E. (2025). Advancing clinical pharmacogenomics worldwide through the Clinical Pharmacogenetics Implementation Consortium (CPIC). *Clinical Pharmacology & Therapeutics, 118*(6), 1512–1522.

[7]Coumau, A., Coumau, C., & Csajka, C. (2025). Implementing pharmacogenetic testing in community pharmacy practice: A scoping review. *Frontiers in Pharmacology, 16*, 1659875.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, September 2026
Impact Factor: 8.2

3.5 Conceptual Framework

The following framework is suggested for the study:

Pharmacogenomic testing leads to improved medication safety and effectiveness, which results in improved clinical outcomes, follows pharmacogenetic testing, and is followed by drug selection/optimization of doses and pharmacogenetic testing, finally, which is followed by genetic variation and pharmacokinetics/pharmacodynamics differences.

In this framework, genetic information should be used in conjunction with traditional clinical parameters. The ultimate goal is to use genomic information to guide effective and individualized pharmacotherapy, in a safe and effective way.

Result

Table 3.1: Thematic Distribution of Reviewed Literature

S. No.	Thematic Area	Number of Studies Reviewed
1	Pharmacogenomics and Drug Response	25
2	Drug Selection and Dose Optimization	22
3	Prevention of Adverse Drug Reactions	18
4	Clinical Implementation and Outcomes	15
Total	**Total Literature Reviewed**	**80**

Interpretation

Thematic distribution of the 80 studies reviewed in this study is shown in Table 3.1. A high percentage of literature, 25 studies, dealt with pharmacogenomics and drug response, reflecting interest in research to understand genetic effects on drug effectiveness and variability. Genotype guided therapeutic decisions are important, and 22 studies were focused on drug selection and dose optimization. 18 studies were focused on preventing adverse drug reactions, highlighting the importance of pharmacogenomics in enhancing the safety of drug use. Lastly, there were 15 studies that focused on clinical implementation and outcomes, reflecting the increased need for pharmacogenomic evidence to be translated into clinical practice and measurable outcomes.[8]



Figure 3.1: Thematic Distribution of Reviewed Literature

[8]Wu, A., Raack, E. J., Ross, C. J. D., & Carleton, B. C. (2025). Implementation and evaluation strategies for pharmacogenetic testing in hospital settings: A scoping review. *Therapeutic Drug Monitoring, 47*(2), 211–247.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, September 2026
Impact Factor: 8.2

IV. PHARMACOGENOMICS, DRUG SELECTION

The most significant uses of PGx are to decide if a specific medication would be suitable for a person.[9]

4.1 CYP2C19 and Clopidogrel

Clopidogrel is a prodrug which must be metabolised, mainly by the enzyme CYP2C19. Individuals with loss-of-function variants have reduced antiplatelet response because of reduced production of its active metabolite by genetic variation of CYP2C19. This gene–drug relationship is clinically relevant as recognized by the FDA. According to the results in the TAILOR-PCI trial, however, genotype-directed therapy does not necessarily lead to statistically significant improvements in all clinical outcomes. Therefore, CYP2C19 testing could potentially aid in tailored antiplatelet therapy in suitable clinical situations.[10]

4.2 HLA Variants and Drug Hypersensitivity

Variants of the human leukocyte antigen (HLA) have been shown to be important in forecasting drug hypersensitivity reactions. HLA-B57:01 is strongly associated with abacavir hypersensitivity and HLA-B15:02 is an increased risk of severe cutaneous reactions after carbamazepine use, which may also be relevant to phenytoin use. Pharmacogenomic testing can thus be used to help identify patients who are genetically susceptible prior to treatment. Here are some examples of how PGx can be used to help prevent adverse drug reactions, to help guide safer drug choice.[11]

V. PHARMACOGENOMICS AND DOSE OPTIMIZATION

Changes in genetic variation may lead to changes in drug concentrations and therefore impact on the dose needed to attain therapeutic exposure.

5.1 CYP2C9 and VKORC1 in Warfarin Therapy (Diabetes!)

Warfarin has significant inter-individual differences in dose requirement, partly as a result of genetic polymorphisms in both the CYP2C9 and VKORC1 genes. CYP2C9 is involved in the metabolism of warfarin and VKORC1 in the sensitivity and pharmacological target of warfarin. The FDA considers these genetic and clinical characteristics to be relevant to warfarin dosing and to be factors to consider when deciding on warfarin therapy. In addition, genotype should be used along with INR measurement and adjustment of dosage. Therefore, the importance of incorporating pharmacogenomic information with traditional clinical management is apparent in the case of warfarin.[12]

5.2 TPMT and NUDT15 in Thiopurine Therapy

An example of pharmacogenomics guided dose optimization is thiopurine drugs. Genetic polymorphisms in TPMT and NUDT15 may affect the metabolism of thiopurines and sensitivity to thiopurine-induced myelosuppression. People with low or no enzyme activity may be more likely to get poisoned during normal doses. Thus, CPIC guidelines advocate for genotype-driven strategies to thiopurine use (such as dose adjustment for genetically susceptible patients). This application shows the value of the pre-treatment genetic information to help identify toxicity risk and to assist with more individualized dosing decisions.[13]

---

[9]El Rouby, N., & Johnson, J. A. (2025). Pharmacogenetic testing—Evidence, challenges, and pathways to adoption. *NEJM Evidence, 4*(10), EVIDra2400343.

[10]Gawronski, B. E., Fofanova, I., Miranda, A. M., Malave, J. G., & Duarte, J. D. (2025). Implementation of clinical pharmacogenetic testing in medically underserved patients: A narrative review. *Pharmacogenomics, 26*(3–4), 107–119.

[11]Ji, Y., Brunk, L., Bove, B., Danyal, K., Langman, L. J., Mot, N., Mroz, P., Natowicz, M., Reddi, H., Shirts, B., Smock, K., Wool, G. D., Zhang, B. M., & Moyer, A. M. (2025). Pharmacogenomic testing: Strategies and technical considerations for clinical laboratories. *Archives of Pathology & Laboratory Medicine, 150*(5), 339–353.

[12]Kanegusuku, A. L. G., Chan, C. W., O'Donnell, P. H., & Yeo, K.-T. J. (2024). Implementation of pharmacogenomics testing for precision medicine. *Critical Reviews in Clinical Laboratory Sciences, 61*(2), 89–106.

[13]McDermott, J. H., Sharma, V., Keen, J., & Newman, W. G. (2025). Embedding pharmacogenetics into clinical practice to improve patient outcomes. *Annals of Human Genetics, 89*(5), 398–405.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, September 2026
Impact Factor: 8.2

VI. DISCUSSION

Pharmacogenomics is a revolution in pharmacotherapy, moving from population -based to treatment more tailored to the individual. Its most important advantage is the ability to provide a description of one part of the biological variability that cannot be fully described by conventional prescribing.

The evidence is even more strong for selected gene–drug relationships where genetic information can help to identify patients who are significantly at risk for toxicity or altered drug exposure. These are just a few examples of the clinical diversity of the PGx applications: HLA variants, DPYD, TPMT, NUDT15, CYP2C9, CYP2C19 and VKORC1.

In the same manner, the evidence must not be exaggerated. The TAILOR-PCI trial is just one of the examples of how there may not be a significant clinical benefit in every endpoint for a biologically strong gene–drug association.

On the other hand, the large European 12-gene implementation study showed that there was a significant decrease in clinically relevant adverse drug reactions in patients treated with genotype-guided therapy.

These seemingly conflicting results are not in contradiction. They provide evidence that PGx is not a "one size fits all" approach. The utility of testing is dependent on the type of medicine, the genetic variant, the disease context, baseline risk, alternatives, testing strategy, clinical workflow, and the outcome measured.

The future of PGx is far from being the time where all patients are tested for all genes. Rather, the field is moving toward “actionable pharmacogenomics,” focusing issues of testing when there is strong evidence that it is warranted, and where genetic information could have a meaningful influence on clinical management.

Interdisciplinary teamwork will also be required for successful implementation. Interpretation and optimization of medication can be done by pharmacists; genetic information can be combined with clinical assessment by physicians; analytical validity can be maintained by the laboratory; clinical decision-support systems can be created by informaticians; and regulatory and reimbursement policies can be developed by policymakers.[14]

VII. LIMITATIONS

This paper is not a systematic review, but a narrative review and conceptual analysis. It therefore does not offer a quantitative meta-analysis of all pharmacogenomic studies that are available.

There are also significant variations in evidence base for gene–drug pairs. Some associations have established clinical recommendations, others are investigational and others have unclear clinical utility. Furthermore, recommendations for pharmacogenomics can evolve as new evidence becomes available.

One drawback is that genetic information is one factor of drug response. Other clinical factors such as renal and hepatic function, concomitant medications, disease state, adherence, environmental and other factors are still important elements of a customised pharmacotherapy approach.[15]

VIII. CONCLUSION

Personalized medication through pharmacogenomics is an important route to safer, more accurate and potentially more effective use of medication. PGx can help select the most appropriate drugs for patients, optimize doses with genetic data, detect patients who are more likely to experience adverse drug effects and explain differences in drug exposure, and inform individual treatment choices.

The most compelling current applications are those of clinically actionable gene–drug relationships where there are evidence-based recommendations. Genetic information can be used to boost medication safety and optimize treatment,

---

[14] Sadee, W., Wang, D., Hartmann, K., & Toland, A. E. (2023). Pharmacogenomics: Driving personalized medicine. *Pharmacological Reviews, 75*(4), 789–814.

[15] Smith, D. M., Douglas, M. P., Aquilante, C. L., Deverka, P. A., Devine, B., Dunnenberger, H. M., Empey, P. E., Hertz, D. L., Monte, A. A., Moyer, A. M., Patel, J. N., Pratt, V. M., Saulsberry, L., Scott, S. A., Voora, D., Woodahl, E. L., Whirl-Carrillo, M., & Oni-Orisan, A. (2025). Progress in pharmacogenomics implementation in the United States: Barrier erosion and remaining challenges. *Clinical Pharmacology & Therapeutics, 118*(4), 778–789.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, September 2026
Impact Factor: 8.2

as shown by examples of genes involved in medications including those for CYP2C19, CYP2C9, VKORC1, DPYD, TPMT, NUDT15, and HLA genes.

However, it is important to understand that the practice of pharmacogenomics must be used in conjunction with, not instead of, clinical medicine. Suggesting a genetic association does not imply clinical utility; implementation needs to be done based on the strength of the evidence.

The continued evolution and development of PGx will rely upon a variety of factors, including integration with electronic health records (EHRs), clinical decision support systems, artificial intelligence (AI), population-specific genomic studies, and evidence-based prescribing guidelines. More needs to be done to make it more affordable, more easily reimbursed, more private, more professionally educated and more equitably available.

The ultimate intent of pharmacogenomics is not just to recognize that there is a genetic difference, but to make clinically relevant decisions that will have positive impacts on the quality, safety, effectiveness, and efficiency of pharmacotherapy.

REFERENCES

1. Caudle, K. E., Whirl-Carrillo, M., Relling, M. V., Hoffman, J. M., Donnelly, R. S., Haidar, C. E., Bourque, M. S., Frear, S., Gong, L., Sangkuhl, K., Whaley, R., & Klein, T. E. (2025). Advancing clinical pharmacogenomics worldwide through the Clinical Pharmacogenetics Implementation Consortium (CPIC). *Clinical Pharmacology & Therapeutics, 118*(6), 1512–1522.
2. Coumau, A., Coumau, C., & Csajka, C. (2025). Implementing pharmacogenetic testing in community pharmacy practice: A scoping review. *Frontiers in Pharmacology, 16*, 1659875.
3. El Rouby, N., & Johnson, J. A. (2025). Pharmacogenetic testing—Evidence, challenges, and pathways to adoption. *NEJM Evidence, 4*(10), EVIDra2400343.
4. Gawronski, B. E., Fofanova, I., Miranda, A. M., Malave, J. G., & Duarte, J. D. (2025). Implementation of clinical pharmacogenetic testing in medically underserved patients: A narrative review. *Pharmacogenomics, 26*(3–4), 107–119.
5. Ji, Y., Brunk, L., Bove, B., Danyal, K., Langman, L. J., Mot, N., Mroz, P., Natowicz, M., Reddi, H., Shirts, B., Smock, K., Wool, G. D., Zhang, B. M., & Moyer, A. M. (2025). Pharmacogenomic testing: Strategies and technical considerations for clinical laboratories. *Archives of Pathology & Laboratory Medicine, 150*(5), 339–353.
6. Kabbani, D., Akika, R., Wahid, A., Daly, A. K., Cascorbi, I., & Zgheib, N. K. (2023). Pharmacogenomics in practice: A review and implementation guide. *Frontiers in Pharmacology, 14*, 1189976.
7. Kanegusuku, A. L. G., Chan, C. W., O'Donnell, P. H., & Yeo, K.-T. J. (2024). Implementation of pharmacogenomics testing for precision medicine. *Critical Reviews in Clinical Laboratory Sciences, 61*(2), 89–106.
8. McDermott, J. H., Sharma, V., Keen, J., & Newman, W. G. (2025). Embedding pharmacogenetics into clinical practice to improve patient outcomes. *Annals of Human Genetics, 89*(5), 398–405.
9. Medwid, S., & Kim, R. B. (2024). Implementation of pharmacogenomics: Where are we now? *British Journal of Clinical Pharmacology, 90*(8), 1763–1781.
10. Mosch, R., van der Lee, M., Guchelaar, H. J., & Swen, J. J. (2025). Pharmacogenetic panel testing: A review of current practice and potential for clinical implementation. *Annual Review of Pharmacology and Toxicology, 65*(1), 91–109.
11. Pereira, N. L., Farkouh, M. E., So, D., Lennon, R., Geller, N., Mathew, V., Bell, M., Bae, J.-H., Jeong, M. H., Chavez, I., Gordon, P., Abbott, J. D., Cagin, C., Baudhuin, L., Fu, Y.-P., Goodman, S. G., Hasan, A., Iturriaga, E., Lerman, A., ... Rihal, C. (2020). Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: The TAILOR-PCI randomized clinical trial. *JAMA, 324*(8), 761–771.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 1, September 2026
Impact Factor: 8.2

12. Sadee, W., Wang, D., Hartmann, K., & Toland, A. E. (2023). Pharmacogenomics: Driving personalized medicine. *Pharmacological Reviews, 75*(4), 789–814.
13. Smith, D. M., Douglas, M. P., Aquilante, C. L., Deverka, P. A., Devine, B., Dunnenberger, H. M., Empey, P. E., Hertz, D. L., Monte, A. A., Moyer, A. M., Patel, J. N., Pratt, V. M., Saulsberry, L., Scott, S. A., Voora, D., Woodahl, E. L., Whirl-Carrillo, M., & Oni-Orisan, A. (2025). Progress in pharmacogenomics implementation in the United States: Barrier erosion and remaining challenges. *Clinical Pharmacology & Therapeutics, 118*(4), 778–789.
14. Swen, J. J., van der Wouden, C. H., Manson, L. E. N., Abdullah-Koolmees, H., Blagec, K., Blagus, T., Böhringer, S., Cambon-Thomsen, A., Cecchin, E., Cheung, K. C., Deneer, V. H., Dupui, M., Ingelman-Sundberg, M., Jonsson, S., Joefield-Roka, C., Just, K. S., Karlsson, M. O., Konta, L., Koopmann, R., ... Guchelaar, H. J. (2023). A 12-gene pharmacogenetic panel to prevent adverse drug reactions: An open-label, multicentre, controlled, cluster-randomised crossover implementation study. *The Lancet, 401*(10374), 347–356.
15. Wu, A., Raack, E. J., Ross, C. J. D., & Carleton, B. C. (2025). Implementation and evaluation strategies for pharmacogenetic testing in hospital settings: A scoping review. *Therapeutic Drug Monitoring, 47*(2), 211–247.